ZOMDF
Zomedica Corp.
+0.00 (+1.60%)0.08USD125K成交股數80.6M市值–本益比(近四季)2.2股價營收比+36.6%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 9.5M+37% | 8.8M+35% | 10.5M+50% | 8.1M+32% | 7.0M+11% | 6.5M-11% | 7.0M+10% | 6.1M+2% | 6.3M | 7.3M | 6.3M | 6.0M |
| 營業成本 | 3.5M | 3.3M | 3.3M | 2.7M | 2.3M | 2.1M | 1.9M | 1.8M | 2.1M | 2.3M | 2.0M | 2.0M |
| 毛利 | 6.0M+29% | 5.5M+24% | 7.2M+42% | 5.4M+25% | 4.7M+13% | 4.4M-13% | 5.1M+16% | 4.4M+8% | 4.1M | 5.1M | 4.4M | 4.0M |
| 毛利率 | 63.5% | 62.3% | 68.5% | 67.2% | 67.0% | 67.8% | 72.3% | 71.1% | 65.7% | 69.1% | 68.7% | 67.2% |
| 研發費用 | 1.1M | 1.2M | 1.6M | 1.8M | 1.9M | 1.9M | 1.8M | 1.5M | 1.8M | 3.1M | 867K | 859K |
| 銷售管理費用 | 5.4M | 5.4M | 6.2M | 5.9M | 6.2M | 6.3M | 6.8M | 8.0M | 8.6M | 2.6M | 6.1M | 9.9M |
| 營業利益 | −4.1M-49% | −4.9M-92% | −5.2M-31% | −6.6M-74% | −8.0M-23% | −64.5M+180% | −7.4M+25% | −25.1M+272% | −10.4M | −23.1M | −5.9M | −6.7M |
| 營業利益率 | -42.9% | -55.7% | -49.3% | -81.6% | -115.4% | -993.0% | -106.3% | -408.9% | -165.9% | -314.5% | -93.7% | -112.0% |
| 稅後淨利 | −3.8M-49% | −4.5M-93% | −4.5M-32% | −6.1M-74% | −7.4M-19% | −63.8M+185% | −6.7M+1264% | −23.9M+356% | −9.2M | −22.4M | −491K | −5.2M |
| 淨利率 | -39.6% | -51.5% | -43.3% | -75.6% | -106.2% | -981.7% | -95.7% | -390.3% | -146.3% | -305.4% | -7.7% | -87.2% |
| 稀釋 EPS | – | 0.00-100% | 0.01-200% | -0.01-50% | -0.010% | -0.07+150% | -0.01 | -0.02+300% | -0.01 | -0.03 | 0.00 | -0.01 |
| 稀釋股數 | – | – | 980M | 980M | 980M | 980M | 980M | 980M | 980M | 980M | 980M | 980M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 7.2M | 9.4M | 9.0M | 7.5M | 8.1M | 8.8M | 9.7M | 7.9M | 10.9M | 13.0M | 21.8M | 28.0M |
| 應收帳款 | 5.7M | 4.4M | 3.0M | 3.1M | 2.3M | 1.6M | 1.8M | 1.4M | 1.6M | 1.2M | 1.3M | 654K |
| 存貨 | 6.1M | 5.9M | 5.5M | 5.5M | 5.7M | 5.4M | 5.4M | 5.5M | 5.1M | 5.1M | 3.7M | 3.6M |
| 總資產 | 118M | 122M | 127M | 131M | 136M | 143M | 214M | 220M | 244M | 253M | 275M | 275M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 10.9M | 10.6M | 11.6M | 11.2M | 11.1M | 10.5M | 11.3M | 11.2M | 11.8M | 13.2M | 14.2M | 15.3M |
| 股東權益 | 107M | 111M | 115M | 120M | 125M | 132M | 203M | 209M | 232M | 240M | 261M | 259M |
| 負債比 | 9.2% | 8.7% | 9.2% | 8.6% | 8.1% | 7.4% | 5.3% | 5.1% | 4.8% | 5.2% | 5.2% | 5.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −5.3M-21% | – | – | – | −6.6M | – | – | −7.6M | – | – | – |
| 資本支出 | – | 60K | – | – | – | 280K | – | – | 2.3M | – | – | – |
| 自由現金流 | – | −5.3M-23% | – | – | – | −6.9M | – | – | −9.9M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -60.4% | – | – | – | -106.6% | – | – | -158.5% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 32.0M
| Therapeutics | 26.2M | 81.8% | +5.4% |
|---|---|---|---|
| Development Services | 3.0M | 9.5% | – |
| Diagnostics | 2.8M | 8.7% | +15.1% |
地區2025 年度 · 32.0M
| 美國 | 26.5M | 82.6% | +17.3% |
|---|---|---|---|
| 美國以外 | 5.6M | 17.4% | +17.8% |
產品／服務2025 年度 · 32.0M
| Consumables Revenue | 20.7M | 64.6% | +17.1% |
|---|---|---|---|
| Capital Revenue | 9.3M | 28.9% | -2.5% |
| Engineering Revenue | 2.0M | 6.2% | – |
| Product And Service Other | 123K | 0.4% | -6.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 32.0M | +17.4% | −81.9M | -255.6% | -0.08 | −18.2M |
| FY2024 | 27.3M | +8.3% | −47.0M | -172.2% | -0.05 | −28.8M |
| FY2023 | 25.2M | +33.0% | −34.5M | -137.1% | -0.04 | −27.3M |
| FY2022 | 18.9M | +358.0% | −17.0M | -89.9% | -0.02 | −12.5M |
| FY2021 | 4.1M | – | −18.4M | -444.8% | -0.05 | −14.4M |
| FY2020 | 0 | – | −16.9M | –% | -0.05 | −16.3M |
| FY2019 | – | – | −19.8M | –% | -0.19 | −15.8M |
| FY2018 | – | – | −16.6M | –% | -0.18 | −11.8M |